NKGen Biotech EBIT

The latest EBIT for NKGN is $1.2M as of March 2025. That compares with $-27M in the prior-year period — up 104.4% year over year. That is above the sector sector average of $-69M. Investors often review this figure alongside NKGen Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, NKGN's EBIT moved from $-27M to $1.2M — a 104.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NKGen Biotech's operating scale or balance-sheet position.

Against its sector companies, NKGN currently prints $1.2M for EBIT, while the sector average sits near $-69M. That is roughly 101.7% above the sector mean. Large gaps often invite a closer look at NKGen Biotech's growth, margins, and balance sheet.

A EBIT figure of $1.2M for NKGN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting NKGN's EBIT ($1.2M), review year-over-year change from $-27M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.